Georgia College

Knowledge Box
Doctor of Nursing Practice (DNP) Translational
and Clinical Research Projects

School of Nursing

Spring 2021

Implementation of an Opioid Risk Assessment Tool in an Acute
Pain Service
Emoshoke Owie
emoshoke.owie@gmail.com

Follow this and additional works at: https://kb.gcsu.edu/dnp
Part of the Nursing Commons

Recommended Citation
Owie, Emoshoke, "Implementation of an Opioid Risk Assessment Tool in an Acute Pain Service" (2021).
Doctor of Nursing Practice (DNP) Translational and Clinical Research Projects. 52.
https://kb.gcsu.edu/dnp/52

This Dissertation is brought to you for free and open access by the School of Nursing at Knowledge Box. It has
been accepted for inclusion in Doctor of Nursing Practice (DNP) Translational and Clinical Research Projects by an
authorized administrator of Knowledge Box.

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL

Implementation of an Opioid Risk Assessment Tool in an Acute Pain Service

Emoshoke Owie
Georgia College & State University

Committee Chair: Flor A. Culpa-Bondal, PhD, RN, PMHCNS/NP-BC

Committee Member: Sandra Copeland, DNP, RN, CNS-BC, FNP-BC
Committee Member: Joy Chang, ANP-BC

Date of Submission: April, 15, 2021

1

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL

2

Acknowledgement
I want to express my deepest appreciation to my committee; Dr. Flor Culpa-Bondal, who
served as my committee chair, Dr. Sandra Copeland, my second committee member and Joy
Chang, ANP-BC, the manager of the Acute Pain Service, for their time, support, patience,
incredible guidance, expertise, and insightful comments and countless feedback provided at
every stage of the research project and dissertation. I was successful because of their top-notch
mentorship. I am forever grateful to them for embarking on this journey with me. Many thanks to
the director and providers at my project site for their support and participation.
I am extremely grateful to my loving and caring husband, Ekpen, who stood by me
through the challenges of navigating this doctoral journey amidst a pandemic. Your unwavering
support and encouragement kept me going. Thank you for the innumerable hours spent listening
to my ideas and being my sounding board. You are truly my backbone. To my beautiful, kind,
and sweet daughters, Izoduwa and Ivie, I appreciate your unconditional love, patience, and
understanding when I had to cancel Girl Scout meetings and fun activities because I had to work
on an assignment. You both are my biggest cheerleaders and my inspiration. I am blessed to have
such amazing daughters who always make me proud.
Special thanks to my sweet mother, Ms. Lilian, for raising me to be the strong woman I
am today. I appreciate your prayers, daily text messages, and words of encouragement. You are
one in a billion. My sincere gratitude to my wonderful siblings, Omuwa, Okuns, and Ayemoba,
for their support, encouragement, time spent proofreading my papers, and listening to my ideas
and presentations. They are the best siblings anyone could ever have.
Most importantly, I am very grateful to God Almighty for the countless blessings He
showered upon me every step of this journey.

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL
Dedication
This project is dedicated to God, my family “the village”, and the people who have lost their
lives from an opioid-related overdose. The fight to end the opioid epidemic continues.

3

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL

4

Table of Contents
Abstract.......................................................................................................................................... 7
Chapter I: Introduction and Background .................................................................................. 9
Background Information ...........................................................................................................................9
Problem Statement ..................................................................................................................................11
Clinical Questions ...................................................................................................................................12
The Purpose of the Project ......................................................................................................................13
Operational Definitions ...........................................................................................................................15
Summary .................................................................................................................................................15

Chapter II: Review of the Literature and Conceptual Framework ....................................... 16
Review of the Literature ..........................................................................................................................16
Opioid Misuse Behaviors ........................................................................................................................16
Risk Assessment Tools ............................................................................................................................20
Validity of Risk Assessment Tools .........................................................................................................22
Clinical Decisions ....................................................................................................................................25
Conceptual Framework ...........................................................................................................................26
Summary .................................................................................................................................................28

Chapter III: Methodology .......................................................................................................... 30
Methodology ...........................................................................................................................................30
Project Design .........................................................................................................................................31
Data Collection ........................................................................................................................................32
Setting ......................................................................................................................................................32
Participants ..............................................................................................................................................33
Ethical Considerations .............................................................................................................................33

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL

5

Measures/Tools/Instruments ...................................................................................................................34
Data Analysis ..........................................................................................................................................36
Summary .................................................................................................................................................38

Chapter IV: Results .................................................................................................................... 39
Sample Characteristics ............................................................................................................................39
DIRE Score Instrument ...........................................................................................................................40
Results by Clinical Question ...................................................................................................................44
Clinical Question .....................................................................................................................................44
Summary .................................................................................................................................................53

Chapter V: Discussion ................................................................................................................ 55
The Study ................................................................................................................................................55
Long Term Opioid Initiation ...................................................................................................................55
Referral to Addiction Specialist ..............................................................................................................56
DIRE Score Utilization and Providers’ Perception .................................................................................57
Strengths and Limitations ........................................................................................................................59
Recommendations for Future Research...................................................................................................59
Implications for Future Practice ..............................................................................................................60
Sustainability ...........................................................................................................................................61
Summary .................................................................................................................................................62
Conclusion ...............................................................................................................................................63

References .................................................................................................................................... 64
Appendices ................................................................................................................................... 71
Appendix A: DIRE Score ........................................................................................................................71
Appendix B: Participation Letter.............................................................................................................72

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL

6

Appendix C: IRB Approval .....................................................................................................................73
Appendix D: Site Permission ..................................................................................................................74
Appendix E: Informed Consent ...............................................................................................................75
Appendix F: Post-Implementation Survey ..............................................................................................77
Appendix G: Permission to Use DIRE Score ..........................................................................................78
Appendix H: Acute Pain Rounding Sheet ...............................................................................................79

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL

7

Abstract
The U.S is currently experiencing a deadly opioid epidemic, as demonstrated by the prevalence
of opioid misuse and overdose-related deaths. Over the last two decades, opioid overdose has
claimed the lives of more than 700,000 Americans; deaths increased by 200% from 2000 to 2014
(National Institute of Health, 2020), and totaled 67,367 in 2018 alone (CDC, 2020). Therefore,
healthcare providers collaborating with other stakeholders must continue to explore and apply
appropriate risk assessment tools to mitigate this crisis, such as a systematic method of risk
stratification. This quality improvement project aims to improve current opioid risk screening
practices conducted by acute pain services (APS) by introducing an opioid risk assessment tool,
the Diagnosis, Intractability, Risk, and Efficacy (DIRE) Score, into clinical practice. The DIRE
Score was designed to be utilized in clinical practice and expected to substantially change
providers’ prescribing decisions. Purposive sampling was used to recruit the participants (N=11),
APS providers from a metropolitan hospital in Atlanta, Georgia. Data was collected
retrospectively, utilizing the DIRE Score and 9-weeks rounding sheet, before and during the 10week project implementation. Lastly, a post-implementation questionnaire survey provided
feedback about the DIRE Score. This research demonstrated no statistically significant
relationship between provider’s initial and final plans to initiate long-term opioid therapy or refer
patients to addiction specialists. However, there was a statistically significant relationship
between patients’ risk level and their providers’ decision to initiate long-term opioid therapy or
refer patients to addiction specialists. The percentage of long-term opioid therapy methods
initiated during the ten weeks of project implementation decreased from pre- to post-assessment.
The providers’ utilization of the DIRE Score increased, and the majority of providers perceived
the DIRE Score to be an easy, helpful guide for making the difficult decision to authorize long-
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term opioid therapy, validating their initial assessment and interventions. The DIRE Score helps
to promote patients’ safety and supports the safe prescription of long-term opioids.

Keywords: DIRE Score, opioids, DIRE, long-term opioid therapy, addiction specialist,
opioid risk assessment tool, Acute Pain Service
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Chapter I: Introduction and Background
Chronic pain constitutes a societal burden. Over 100 million Americans suffer from
chronic pain, resulting in national health care costs of over $600 billion and the loss of workers’
productivity (Harle et al., 2015). Dowell et al. (2016) estimated that 20% of patients that visited a
physicians’ office complaining of noncancer pain symptoms or a pain-related diagnosis received
an opioid prescription. In 2012, providers wrote more than 259 million prescriptions for opioids,
defined as medicines that contain chemicals used to relax the body and relieve pain (National
Institute on Drug Abuse (NIDA), 2019).
Butler et al. (2014) found that the rise in the number of written opioid prescriptions was
due to a new awareness of undertreated pain, and this uptick in opioid prescriptions led to an
increase in opioid use disorder (OUD). In 2016, 11.8 million people aged 12 and over reported
improperly using opioid prescriptions in the United States, accounting for 4.4% of the population
(Ahrnsbrak et al., 2016). In addition, 953,000 people received treatment for the misuse of opioid
pain relievers in 2017 (Center for Behavioral Health Statistics and Quality, 2018).
Opioid abuse presents serious risks, including overdose and death. Deaths from opioid
overdose increased by 200% between 2000 and 2014 (National Institute of Health, 2020), and in
2018, there were 67,367 drug overdose deaths in the U.S. (CDC, 2020). Therefore, healthcare
providers must collaborate with other stakeholders to explore and apply appropriate risk
assessment tools to mitigate this crisis.
Background Information
Since 1999, opioids have claimed the lives of more than 700,000 Americans; currently,
this amounts to an average of 130 deaths per day (Tawil, 2019). In 2017, facing annual deaths of
about 47,600 people, the United States government confirmed the opioid crisis as a public health
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emergency (Borsari & Read, 2019). In 2009, the Center for Disease Control and Prevention
(CDC) reported that 1.2 million emergency department visits were related to the misuse or abuse
of opioids (2011). According to results from the 2017 National Survey on Drug Use and Health,
an estimated two million Americans misused prescription pain relievers for the first time within
the past year, which averages approximately 5,480 initiates per day (National Institute on Drug
Abuse, 2018). Zgierska et al. (2018) proposed that, to end the opioid crisis and reduce the rate of
opioid misuse, providers should not start at-risk patients on opioid therapy.
A systematic review of chronic opioid treatment for chronic noncancer pain by Chou et
al. (2009) strongly recommended conducting screenings of patients’ history and risk levels for
substance abuse, misuse, and addiction before initiating chronic opioid therapy. Furthermore, the
review suggested that healthcare providers in inpatient practices must do their part to mitigate
opioid use disorder (OUD); inpatient clinical practices play a pivotal role in delivering healthcare
services, especially pain management (Chou et al., 2009).
As a translational clinical research project (TRCP), the primary investigator (PI)
implemented the utilization of an opioid risk assessment tool into an acute care pain management
group, the acute pain service (APS). When a patient’s provider places a pain management
consult, APS providers assess the patient and formulate a pain regimen. This assessment
currently does not include the use of a validated opioid risk assessment tool to screen patients for
compliance, or for their risk for opioid abuse and/or misuse. Given the current state of the opioid
epidemic, screening chronic pain patients for opioid risk levels and aberrant drug behaviors
before they start long-term opioid therapy is paramount.
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Problem Statement
Opioids can depress the areas of the brain that control breathing, heart rate, and body
temperature, causing them to stop functioning. If started on long-term opioid therapy without
proper supervision or screening, patients who are high risk for opioid abuse and/or misuse could
overdose on their prescribed opioids and die. Stakeholders such as the Center for Disease
Control and Prevention (CDC), the Food and Drug Administration (FDA), the American Pain
Society, and the American Academy of Pain Medicine have highlighted the importance of
assessing patients for risk of opioid abuse to ease the ongoing opioid epidemic (Dowell et al.,
2016). Belgrade et al. (2016) developed an opioid risk assessment tool, the Diagnosis,
Intractability, Risk, and Efficacy (DIRE) Score (see Appendix A) and stressed the need to
identify a strategy for selecting patients who are the most likely to comply with, and benefit
from, prescribed opioids. Dr. Jerome Adams, the former United States Surgeon General,
emphasized the importance of behavioral health and risk factor assessments when prescribing
opioids; providers that prescribe opioids for pain management should use these tools and
assessments to help inform their treatment decisions (Substance Abuse and Mental Health
Services Administration, 2018). When used in combination with a standardized clinical
examination, validated risk assessment tools have been shown to improve the ability to detect
opioid misuse; they have similarly improved providers’ ability to detect aberrant behaviors in
patients, such as soliciting opioids from other providers, forging prescriptions, and using
additional opioids on top of those prescribed to them (Ducharme & Moore, 2019). These tools
support providers in pinpointing at-risk patients’ aberrant drug behaviors.
However, the APS does not routinely screen patients using an opioid risk assessment tool
(ORAT) before starting long-term opioid treatment. This project sought to implement an ORAT,
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specifically the Diagnosis, Intractability, Risk, and Efficacy (DIRE) Score, in clinical practice. In
addition to a comprehensive assessment, consistent usage of the DIRE Score could provide the
APS with a standardized approach for assessing the risk of opioid-related harms before
prescribing long-term opioids. The DIRE Score could also support clinical decisions to initiate
long-term opioids or refer patients to an addiction specialist.
Clinical Questions
The DNP project sought to answer the following questions:
Clinical Question 1: What are providers’ initial and final plans for initiating long-term opioid
use in acute pain service patients?
Clinical Question 2: What is the relationship between providers’ initial plans for initiating longterm opioid use in acute pain service patients and their final plans for initiating long-term opioid
use?
Clinical Question 3: What is the relationship between patients’ risk level and providers’ final
plans for initiating long-term opioid use?
Clinical Question 4: What are providers’ initial plans and final plans for referring acute pain
service patients to an addiction specialist?
Clinical Question 5: What is the relationship between providers’ initial plans for referring acute
pain service patients to an addiction specialist and their final plans for referring acute pain
service patients to an addiction specialist?
Clinical Question 6: What is the relationship between patients’ risk level and providers’ final
plans for referring acute pain service patients to an addiction specialist?
Clinical Question 7: What percentage of the total number of patients were started on long-term
opioids before and during the project implementation according to the acute pain rounding sheet?
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Clinical Question 8: What is the providers’ utilization of the DIRE Score at two, four, six, eight,
and ten weeks?
Clinical Question 9: What are providers’ perceptions regarding the DIRE Score after ten weeks
of utilization?
The Purpose of the Project
This project aimed to implement the DIRE Score in an acute pain service. Screening
patients hospitalized with acute or chronic noncancer pain for the risk of opioid abuse before
initiating long-term opioids could help mitigate opioid abuse and misuse after they are
discharged. Providers can use this tool to improve patient assessments, thus minimizing risk and
maximizing benefits, especially for those on long-term opioid therapy. The study’s primary
desired outcome was for providers to adopt a standardized screening approach using a validated
tool to assess risks before starting long-term opioid treatment on patients. The goal of these
measures is to promote patient safety and ease the ongoing opioid epidemic. Patients deemed
inappropriate for long-term opioid therapy will be identified based on risk assessment scores, and
providers will make appropriate recommendations or referrals before the patient leaves the
hospital.
Needs Assessment
The principal investigator (PI) initiated a needs assessment with acute pain services
(APS) to identify potential enhancements to quality improvement measures. The site for this
project was a hospital in metro Atlanta, in which APS practiced. When a patient’s provider
places a pain management consult, APS providers perform a focused exam of patients’ history
and physical state and, with that information, formulate a pain management plan. This approach
does not include the use of a validated opioid risk assessment tool to screen patients for
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compliance or their risk for opioid abuse and/or misuse, which is vital in light of the continuing
opioid epidemic.
Following an interview with the APS manager, the PI identified the need to improve
screening and assessment methods for opioid prescription using systematic practices. The PI
further discussed implementing the DIRE Score during a staff meeting, in which providers were
receptive. They verbalized the importance of using a risk assessment tool as the standard of
practice, which can help validate their decisions when initiating long-term opioid therapy,
especially long-term opioid analgesics such as Fentanyl, OxyContin, and MS Contin.
The APS typically gets contacted for a pain management consultation by another
provider. For instance, a patient admitted to the hospital because of uncontrolled chronic back
pain is now in acute pain. The APS can either initiate a new therapy, resume previous home
therapy, or modify existing treatment. Patients believed to be at risk for opioid misuse are not
accepted for pain management treatments conducted by the APS. Rather, they recommend that
patients follow up with an addiction specialist and continue to communicate with their pain
management providers.
The CDC guideline for prescribing opioids recommends that providers evaluate risk
factors for opioid-related harm and incorporate risk mitigation strategies into the management
plan both before starting opioid therapy and periodically during its continuation (Dowell et al.,
2016). Similarly, a systematic review of chronic opioid therapy for chronic noncancer pain by
Chou et al. (2009) strongly recommended that providers assess patients’ history, physical health,
and their risk of substance abuse, misuse, or addiction before initiating chronic opioid therapy. It
is the assumption of this project that patients who are prescribed long-term opioids without an
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objective measure of the risk, or a standardized risk assessment tool, are deemed low-risk
according to providers’ subjective judgment.
Operational Definitions
A review of precise operational definitions and concepts is an essential component of this study.
The relevant terms in this research project are:
Initial plans for long-term opioid use (LTO)-PRE-DIRE Score - providers’ decision to
initiate long-term opioids before using the DIRE Score.
Initial plans for a referral to an addiction specialist (RAS)-PRE-DIRE Score –
providers’ decision to recommend a referral to an addiction specialist before using the
DIRE Score.
Final plans for long-term opioid use-(LTO)-POST-DIRE Score – providers’ decision to
initiate long-term opioids after using the DIRE Score.
Final plans for a referral to an addiction specialist (RAS)-POST DIRE Score –
providers’ decision to recommend a referral to an addiction specialist after using the
DIRE Score.
Summary
Mitigating the opioid misuse epidemic cannot be overemphasized given the loss of lives
and attendant resources. Stakeholders have recommended a systematic approach to screen
patients to minimize the potential for OUD by identifying aberrant drug behaviors. Since
inpatient clinical centers with hospital privileges provide pain management services, clinicians
must adopt standardized screening tools in these centers. This chapter highlighted the
background, problem statement, clinical questions, and needs assessment of the proposed
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project. In the next chapter, an in-depth literature review described the foundations of
knowledge of the project.
Chapter II: Review of the Literature and Conceptual Framework
Review of the Literature
A comprehensive literature search was performed using select databases such as
CINAHL®, MEDLINE®, ProQuest Central®, Academic Search Complete, and Google
Scholar®. The search terms used to find articles included ‘opioid risk tools,’ ‘clinical decision
making,’ ‘risk assessment tools,’ and ‘opioid misuse behaviors,’ used both separately and in
conjunction. The literature consisted of clinical studies, cross-sectional studies, surveys, and
interviews.
Opioid Misuse Behaviors
Patients who abuse opioid prescriptions exhibit several aberrant drug behaviors.
According to Ferrari et al. (2014), an aberrant drug behavior is any medication-related behavior
that departs from strict adherence to the prescribed therapeutic plan of care. Examples of
aberrant behaviors include using additional opioids outside of those prescribed, forging a
prescription, soliciting opioids from other providers, reporting lost or stolen prescriptions,
requesting early refills, overdose, and death (Webster & Webster, 2005).
Fleming et al. (2008) conducted a large-sample study (n=904) to determine the frequency
of aberrant drug behaviors and their relationship to substance abuse disorders. These patients
received opioids for chronic pain from 2002 to 2004 in 235 primary care physicians in eight
Wisconsin counties. Participants completed nine written questionnaires and five interview-based
surveys. Twelve aberrant drug behaviors in the questionnaire included: (1) purposely oversedated oneself with opioids, (2) felt intoxicated from opioids, (3) had a motor vehicle accident
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while taking opioids, (4) requested an early refill, (5) increased opioid dosage without physician
consent, (6) lost or had opioids stolen, (7) tried to obtain opioids from more than one clinician,
(8) successfully obtained opioids from more than one clinician, (9) used opioids for purposes
other than that prescribed, (10) used alcohol to deal with pain, (11) missed an appointment for a
pain condition, and (12) hoarded opioid medication. The study concluded that 80.5% of the
patients reported one or more lifetime aberrant drug behaviors, the most frequent being
requesting early refills (41.7%), increased dose without physician consent (35.7%), and felt
intoxicated from opioids (32.2%). A logic model found that subjects who reported four or more
aberrant behaviors were more likely to have a current substance use disorder.
Screening tools help providers detect whether a patient is currently addicted to or abusing
prescription medications. Several studies concluded that opioid screening tools were useful for
predicting and detecting aberrant behaviors (Webster & Webster, 2005; Larance et al., 2015;
Moore et al., 2009; Jones et al., 2015; Varney et al., 2018). Larance et al. (2015) completed a
cross-sectional study that developed a brief scale, the Opioid-Related Behaviors In Treatment
(ORBIT), which identifies and quantifies recent aberrant behaviors among diverse populations
receiving long-term opioid treatment. Four hundred twenty-six patients, recruited from 57 retail
pharmacies in two Australian jurisdictions and four pain clinics, were prescribed opioids for a
minimum of three months or longer. They completed a 40-item opioid-related survey that
included one item per identified aberrant behavior or related matter. The survey created a 10item scale that showed validity, acceptable test-retest reliability, and adaptability to both clinical
and research settings to monitor patient progress. The Pearson’s correlation was r = 0.80, p <
0.01; in terms of internal consistency, Cronbach’s alpha = 0.89. The study concluded that the
ORBIT would help prompt clinical decisions and aid in the detection of aberrant behavior.
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Moore et al. (2009) completed a comparative study that employed different opioid riskassessment tools to determine how accurately these measures were in predicting the risk of
aberrant drug-related behavior. The convenience sample included 48 patients who attended a
pain clinic in Knoxville, TN after their opioid treatment was halted due to aberrant drug-related
behavior. Participants completed a standard packet of questionnaires, including SOAPP®, ORT,
and DIRE Score, and underwent a semi-structured clinical interview with the staff psychologist
before receiving opioid analgesics for pain management. They were also required to attend
regular appointments, provide urine samples, and adhere to proper medication and clinical
guidelines. At the end of the study, the analysis compared the sensitivity of each self-reported
measure with the results of the clinical interviews to predict the likelihood of discontinuance
because of aberrant drug-related behavior. The results showed that the sensitivity score was 0.77
for the clinical interview, 0.72 for SOAPP, 0.45 for the ORT, and 0.17 for DIRE Score. When
the results of the clinical interviews and SOAPP questionnaires were combined, sensitivity
increased to 0.90, which demonstrated that these measures were the most effective at predicting
discontinuance of opioid therapy due to aberrant drug-related behaviors.
Similarly, Jones et al. (2015) completed a comparative study of a new patient-completed
risk tool known as the Brief Risk Questionnaire. The study compared it with a structured clinical
interview and two risk assessment tools, ORT and SOAPP®-R, to predict aberrant behavior at a
six-month follow-up. The 454 pain-clinic patients were given a packet that contained the BRQ,
the ORT, and SOAPP®-R. They also received other assessment tools, such as the Distress
Thermometer, the Zung Depression Scale, the Zung Anxiety Scale, the Pittsburgh Sleep Quality
Index, the Pain Catastrophizing Scale, and a clinical interview. Researchers gathered information
by reviewing patients’ medical records, the disposition of the cases at the six-month follow-up,
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and the presence or absence of aberrant behavior during this period. The study concluded that the
BRQ could better predict future aberrant drug behavior than the ORT and SOAPP®-R, and it
could be a useful tool for conducting opioid risk assessments.
Varney et al. (2018) conducted a prospective observational study of adult patients
consisting of uniformed members, retirees, and family members over 18 years of age seeking
treatment in a high-volume emergency department. The study, designed to determine if validated
tools such as the SOAPP®-R, COMM, and provider’s gestalt therapy could identify patients at
risk for prescription opioid misuse through their pharmacy records, recruited 163 patients via
convenience sampling. The study concluded that providers could use gestalt and validated
patient self-assessment tools to identify at-risk patients.
Webster and Webster (2005) completed a study to provide clinicians with a brief
screening tool that could be used to predict which individuals may develop aberrant behaviors
when prescribed opioids for chronic pain. One hundred eighty-five patients were recruited from a
pain clinic from January 2000 to May 2001 and asked to complete the ORT, which consists of
five items: family and personal history of alcohol, illegal drug and prescription substance abuse,
age, history of pre-adolescent sexual abuse, and specific mental disorders. Patients received
scores of 0-3 (low risk), 4-7 (moderate risk), or > 8 (high risk), which indicated their probability
of displaying opioid-related aberrant behavior. The study concluded that 17 out of 18 patients in
the low-risk category (94.4%) did not display aberrant behavior; however, 40 out of 44 (90.9%)
patients in the high-risk category did so.
These studies have shown that opioid risk assessment tools help detect aberrant
behaviors. The ORT and the BRQ both demonstrated validity and accuracy in predicting whether
patients were high- or low-risk for opioid-related aberrant behavior. Using these tools, providers
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can modify patients’ treatment plans according to their individual risk profiles, allowing more
accurate identifications of high-risk patients and more appropriate recommendations or referrals
to an addiction specialist.
Risk Assessment Tools
The national standard for chronic pain care now requires that patients undergo risk
stratification before beginning opioid therapy (Jones et al., 2015). Validated screening tools
should be used to accomplish this assessment. There are three types of risk assessment
instruments designed to detect different dangers: opioid misuse before initiating long-term opioid
therapy, signs of misuse in patients currently using opioids, and lastly, non-opioid general
substance abuse. Providers can use various risk assessment tools to conduct risk stratification,
such as the Diagnosis, Intractability, Risk, Efficacy (DIRE) Score, the Opioid Risk Tool (ORT),
the Screener and Opioid Assessment for Patients with Pain® (SOAPP®) and its revision the
(SOAPP®-R), the Screening Instrument for Substance Abuse Potential (SISAP), the Opioid
Compliance Checklist (OCC), the Opioid-Related Behaviors in Treatment (ORBIT), the Pain
Medication Questionnaire, the Brief Risk InterviewÓ (BRI)Ó, and the Brief Risk Questionnaire
(BRQ). Providers can also use the Alcohol Use Disorders Identification Test (AUDIT) to screen
non-opioid general substance abuse. Tools such as the DIRE Score and PDAT are clinician-rated
instruments, while tools such as the ORT, SISAP, and SOAPP®-R are patient self-assessment
instruments (Cheattle, 2019).
Greene et al. (2017) conducted a study on 1,538,120 patients receiving opioids to identify
factors that increase the likelihood that a patient will engage in opioid-related risk behaviors;
researchers used INSPECT and the Prescription Drug Monitoring Program (PDMP) to conduct
this study for the state of Indiana. The PDMP is a statewide electronic surveillance program that
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collects pharmacy information each time a controlled substance is dispensed. It can be used as
both a screening tool and a clinical tool that assists and supports the decision-making process for
patients receiving opioids. Four risk behaviors were identified: patients receiving > 90
milligrams of morphine or equivalent, having >4 opioid prescribers, obtaining opioids from >4
pharmacies, and using benzodiazepines. The result showed that 18.4% engaged in one, 5.3%
engaged in two, 1.6% engaged in three, and 0.4% engaged in all four risk behaviors: about onefourth of all patients consuming opioids engaged in one or more risk behaviors. The use of the
PDMP as a screening tool helped identify opioid users at high risk for misuse.
Oliva et al. (2017) conducted a quality improvement project to develop a clinical decision
support tool to help identify patients at greater risk for overdose or suicide-related events in the
Veteran Health Administration (VHA). The Stratification Tool for Opioid Risk Mitigation
(STORM) tool was designed to combine data elements to calculate risk scores using riskmitigation strategies. The study included patients with active short- or long-acting opioids
analgesic prescriptions from the VHA. Researchers retrieved data from 1,135,601 participants
from the electronic medical record (EMR) and used a predictive model to classify patients based
on risk for overdose/suicide-related adverse events, which allowed high-risk patients to be
identified. The area under the curve (AUC) for the STORM tool was reasonably accurate at >
0.81. The study concluded that clinical informatics could leverage EMR extracted data to
identify patients at risk for overdose/suicide-related events and provide clinicians with
information to mitigate risk.
Kavukcu et al. (2015) conducted a cross-sectional study of 36 physicians working at a
family health center with the goal of enhancing primary care physicians’ knowledge, attitudes,
and practices about opioid use through education on risk assessment. The researchers surveyed
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participants on patients’ risk assessment in both intervention and control groups; the intervention
group received education about assessment for the risk of opioid use, but the control group did
not. The survey was repeated after six months, and the intervention group underwent a core
examination. The results showed that 61% of family physicians reported concern and hesitation
in prescribing opioids due to known risks, such as overdose, addiction, dependence, or diversion,
and agreed that family physicians should apply risk assessment before prescribing opioids for
chronic noncancer pain.
Salinas et al. (2012) conducted a study utilizing a nationally distributed case vignette
survey of primary care physicians (PCP), pain specialists, and pharmacists, in addition to chart
reviews and surveys of patients with chronic pain. From March 2011 to May 2011, the study
aimed to better understand healthcare professionals’ current knowledge, perception, and clinical
practice patterns regarding the prescription of long-acting opioid therapy to patients with chronic
pain. The study results showed that many PCPs are inadequately performing opioid risk
assessments. Also, the accuracy of opioid risk assessments can vary, which can result in PCPs
misestimating patients’ risk level, further establishing the importance of standardized opioid risk
assessment tools.
Validity of Risk Assessment Tools
Belgrade et al. (2006) completed a retrospective analysis to test the DIRE Score’s
validity, and predicted that chronic pain patients would have effective analgesia and long-term
opioid maintenance treatment. The DIRE Score consists of four factors: Diagnosis, Intractability,
Risk, and Efficacy. The risk subcategories, psychological state, chemical health reliability, and
social support, are rated separately and then added together to form the DIRE Score, which is
used to determine if a patient is suitable for long-term opioid analgesia. DIRE Scores were then
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assigned to 61 cases from the pain center’s database, and the cases were abstracted into
vignettes, which six physicians scored. Researchers conducted repeat scoring for 30 new
vignettes after two weeks. The study concluded that the DIRE Score’s internal consistency was
high (Cronbach’s alpha = .80). The sensitivity was 94% and specificity was 87%. The intraclass
correlation was 0.94 for interrater reliability and 0.95 for intra-rater reliability.
Reliability: Based on the retrospective study of Belgrade et al. (2006), the internal
consistency of the DIRE Score has a Cronbach alpha of .80. This study tested the reliability and
validity of the DIRE Score, with three outcomes measures: the global impression of the efficacy
of opioid analgesia, the global impression of compliance with prescribing process, and
disposition with regards to the continuation of opioids at the last clinical contact. The DIRE
Score’s sensitivity and specificity for predicting patient compliance to long-term opioid therapy
were 94% and 87%, respectively. When analyzing efficacy, the specificity and sensitivity were
76% and 81%, respectively, and lastly, for disposition, the specificity and sensitivity were 73%
and 85%, respectively (Belgrade et al., 2006). The intraclass correlation was 0.94 for interrater
reliability and 0.95 for intrarater reliability (Terry, 2018).
Validity: According to Belgrade et al. (2006), the validity of the factors making up the
DIRE Score was strong. This conclusion was based on feedback from clinicians who had used
the tools in their practice. When the chi-square test was used for trends, all factors except for
diagnosis showed a significant relationship (P<0.001) with compliance. Intractability was the
only factor that did not show a significant association (P <0.05) with efficacy. Other than
diagnosis, all factors showed a significant relationship with the disposition (P< 0.05) (Belgrade
et al., 2006).
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Similarly, Ferrari et al. (2014) conducted an observational, prospective, longitudinal
study to evaluate the predictive validity of the PMQ and the DIRE Score in chronic pain patients.
Seventy-five patients were recruited from a pain management unit of San Bortolo Hospital in
Vicenza and Sant’Antonio Hospital in Padua. Researchers followed them between December
2009 and January 2012, and evaluated all patients’ risk of opioid misuse using the PMQ (patientcompleted) and the DIRE Score (filled out by a multidisciplinary team). The patients also went
through medical and psychological screening at two, four, and six months. The study concluded
that the PMQ demonstrated good internal consistency (Cronbach’s alpha = 0.77) and test-retest
reliability (r = 0.86). Researchers found significant correlations between higher PMQ scores and
the number of aberrant drug behaviors detected at two, four, and six-month follow-ups (P< 0.01).
The DIRE Score also demonstrated good predictive validity, as significant correlations were
found between a lower total DIRE Score (higher risk of opioid misuse) and a higher number of
aberrant drug-related behaviors detected at two months (r = -0.37; P < 0.01), four months (r = 0.35; P< 0.01), and six months (r = -0.34; P< 0.01).
Jamison et al. (2016) conducted a study to assess the efficacy of the Opioid Compliance
Checklist (OCC) for monitoring opioid adherence among chronic pain patients in multiple
primary care centers who were prescribed long-term opioid therapy. Researchers recruited 177
chronic pain patients from eight primary care centers, who completed pre-and post-study
measures, as well as the OCC, once a month for six months. Patients were classified on the Drug
Misuse index based on urine toxicology screens, physicians’ misuse behavior ratings, and selfreport questionnaire results. Three items from the OCC were most predictive of opioid misuse,
which researchers determined by measuring and analyzing the area under the curve
(AUC= .861). Patients that scored lower on the OCC showed greater compliance with their
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opioid medication. The OCC seems to be a reliable and valid screening tool to help detect
current and future aberrant drug-related behavior and nonadherence among chronic pain patients
in primary care. Validated screening tools like the DIRE Score, PMQ, and OCC have been
successfully used to identify patients at risk for opioid misuse.
Clinical Decisions
The literature shows that screening tools can help identify opioid abuse. Consequently,
several studies have focused on both how providers approach the patient screening process with
or without standardized tools and their level of confidence about their opioid risk assessment
decisions (Harle et al., 2015; Pearson et al., 2017). Studies by Webster and Webster (2005),
Larance et al. (2015), Moore et al. (2009), Jones et al. (2015), and Varney et al. (2018) have
shown that using opioid risk assessment tools helps detect aberrant behaviors, supports decision
making, and boosts providers’ confidence levels when deciding to initiate opioid therapy.
Harle et al. (2015) conducted an in-depth interview with 15 family and general medicine
physicians to understand how providers view their decisions to prescribe opioids for chronic
noncancer pain (CNCP). The study revealed that providers often rely on their own individual
assessment of patients’ risk level for aberrant drug-related behaviors, such as opioid abuse,
despite recognizing that they may make inaccurate assessments. Some physicians even actively
avoid the chronic pain management field because of their concerns about opioid risks. The
researchers proposed that clinical leaders, educators, and policymakers should continue to create
and disseminate evidence-based education on chronic pain and opioid risk assessment.
Pearson et al. (2017) conducted an Opioid Therapy Provider survey to investigate the
association between provider confidence in managing chronic pain and their practice behaviors
and demographics. The survey was offered to 103 providers (physicians, physician assistants,
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nurse practitioners, and other prescribing providers) that attended the Mayo Clinic Opioid
Conference: Evidence, Clinical Considerations, and Best Practice. The survey results showed
that 60.8% of the respondents did not feel confident managing patients with chronic pain. The
providers’ confidence was positively correlated with: following an opioid therapy protocol
(P=0.001), the perceived ability to identify patients at risk for opioid misuse (P=0.006), and
using a practice-based approach to improve their comfort level (P<0.001). The study concluded
that providers’ confidence was associated with a protocolized, consistent, practice-based
approach towards managing opioids and their perceived ability to correctly identify patients at
risk for opioid misuse.
Conceptual Framework
Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) was
used as the theoretical framework for this project. RE-AIM was initially developed in 1999 by
Russell Glasgow, Shawn Boles, and Thomas Vogt, as a framework for the consistent
reporting of research results. It was later used to organize reviews of existing literature on
health promotion and disease management in different settings (Glasgow et al.,1999). The
following questions guided the implementation process:
1. How do I reach the targeted population?
2. How do I know my intervention is effective?
3. How do I develop the institutional support to deliver my intervention?
4. How do I ensure the intervention is adequately delivered?
5. How do I incorporate the intervention so it is delivered over the long-term?
The five-dimensional RE-AIM framework was instrumental in guiding the implementation of
this project.
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Reach refers to the targeted audience or individuals willing to participate in a given
intervention. The PI reached out to 11 acute pain service providers, targeted because they
provide pain management in an acute care setting, and 11 agreed to participate.
Effectiveness is an intervention’s impact on essential outcomes, including potential
adverse effects. The overall goal is to mitigate the opioid crisis by equipping providers who
prescribe opioids with an objective method to screen patients before initiating long-term
opioid therapy. Positive feedback attained from the post-implementation survey about the use
of the DIRE Score showed that it was implemented effectively.
Adoption refers to the proportion and representativeness of settings and intervention
agents who are willing to initiate the program. Eleven nurse practitioners received education
via a PowerPoint® presentation, and they began screening with the tool for ten weeks.
Implementation involves the intervention agents’ fidelity to the adaptations of
intervention and its associated strategies for implementation. Over a ten-week period, the APS
providers used the DIRE Score to screen patients who required pain management before
deciding to either initiate long-term opioid therapy or refer patients to an addiction specialist.
Maintenance is the extent to which a program is integrated into an organization’s
routine practices and policies. This project implemented an opioid risk assessment tool in an
acute pain service so that providers could use it to screen patients requiring opioid therapy in
their clinical practice. Incorporating the DIRE Score into the electronic health record will
make the DIRE Score easily accessible to all providers and promote routine use in the future.
It was utilized in different stages to evaluate the success of the project, as shown by
Figure 1.
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REACH: APS Nurse
Practitioners
recruited for project,
11 recruited, 11
participated

MAINTENANCE:
Ongoing, APS may
permanently
implement DIRE
Score, and integrate
into EMR

IMPLEMENTATION:
Nurse Practitioners
screened and decided
to initiate LTOT or
RAS. Utilization rate
was monitored

EFFECTIVENESS:
Positive feedback on
post-implementation
survey

ADOPTION: 11 Nurse
pracitioners recieved
education and began
screening with the
DIRE Score

Figure 1.
Application of the Reach, Effectiveness, Adoption, Implementation, Maintenance Framework.
The study by Strand et al. (2020) also used the RE-AIM model to evaluate an opioid and
Naloxone education program, which identified strengths in the areas of efficacy, adoption, and
maintenance, and highlighted the need for improvement in the areas of reach and
implementation. Similarly to this project, studies focused on changing individual behavior have
also used RE-AIM as their framework (King et al., 2010). RE-AIM has also been used in the
study of diverse health areas to plan and assess progress, report results, and review existing
literature (Gaglio et al., 2013).
Summary
The literature review detailed in this chapter showed that patients who abuse their opioid
prescriptions also show aberrant drug behaviors. Providers can use validated screening tools to
identify such aberrant behaviors and inform their judgment to recommend long-term pain
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management regimens for patients. Using opioid risk assessment tools can support providers’
decision making and boost their confidence levels when deciding to initiate opioid therapy.
This project introduced a validated screening tool, the DIRE Score, in an APS group to
support providers in screening patients. The project also shows the utility of the RE-AIM
theoretical framework for instituting organizational change. The next chapter discusses the
project’s methodology, design, and ethical considerations.
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Chapter III: Methodology
Methodology
The PI carried out a quality improvement project in an acute pain service to promote
patient safety and promote safe prescribing practices. The providers used the DIRE Score to
screen patients requiring pain management and considered for long-term opioid therapy. This
DNP project sought to answer the following clinical questions:
Clinical Question 1: What are providers’ initial plans and final plans for initiating longterm opioid use in acute pain service patients?
Clinical Question 2: What is the relationship between providers’ initial plans for
initiating long-term opioid use in acute pain service patients and their final plans for
initiating long-term opioid use?
Clinical Question 3: What is the relationship between patients’ risk level and providers’
final plans for initiating long-term opioid use?
Clinical Question 4: What are providers’ initial plans and final plans for referring acute
pain service patients to an addiction specialist?
Clinical Question 5: What is the relationship between providers’ initial plans for
referring acute pain service patients to an addiction specialist and their final plans for
referring Acute pain service patients to an addiction specialist?
Clinical Question 6: What is the relationship between patients’ risk level and providers’
final plans for referring acute pain service patients to an addiction specialist?
Clinical Question 7: What percentage of the total number of patients were started on
long-term opioids before and during the project implementation according to the acute
pain rounding sheet?
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Clinical Question 8: What is the providers’ utilization of the DIRE Score at two, four,
six, eight, and ten weeks?
Clinical Question 9: What are providers’ perceptions regarding the DIRE Score after ten
weeks of utilization?
Project Design
This descriptive mixed methods quality improvement project introduced an opioid risk
assessment tool, the DIRE Score, to the providers at an acute pain service group. The providers
utilized the DIRE Score to assess patients for risks of opioid misuse before starting pain
management therapy.
Before the Implementation of the DIRE Score
A review of the providers’ APS rounding sheet revealed the number of patients initiated
on long-term opioids in May and June, nine weeks before implementing the DIRE Score.
Providers wrote any modifications to the patient’s plan on the sheet, allowing for continuity of
care, as they may not see the same patients every day. The PI contacted providers via e-mail to
invite them to the research. Informed consent was sent and signed electronically. Also, the PI
emailed each participant a PowerPoint® Presentation on how to use the DIRE Score.
DIRE Score Implementation
During project implementation, providers conducted their standard assessment and
responded to two clinical decision questions. The two questions were: (1) would you initiate
long-term opioids, or, (2) would you recommend a referral to an addiction specialist? Providers
then used the DIRE Score on the same patient to assess for opioid misuse risks, computed a score
for the patient, and then responded to the same two clinical decision questions previously asked.
After Project Implementation
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The PI sent out a post-implementation questionnaire survey consisting of mostly openended questions to providers, to obtain their feedback on the DIRE Score. Next, the PI reviewed
the APS rounding sheet to assess the number of patients initiated on long-term opioids during the
implementation, and entered the data from both tools into SPSS for analysis.
Data Collection
The PI used the APS rounding sheet to obtain the number of long-term opioids initiated,
in the nine weeks before and ten weeks during the project implementation, and used the clinical
decision questions on the DIRE Score forms to count the total number completed and the
patients’ DIRE Scores. The PI remained available to provide support throughout the ten weeks of
project implementation.
Setting
The PI conducted this project within a specialty group, the acute pain service, which
provides in-patient pain management services in a metro Atlanta acute care hospital system,
during the global COVID-19 pandemic. Clients are typically surgical patients with acute pain, or
those admitted with acute pain and/or a history of chronic pain. The APS typically receives a
request for an expert consultation from a provider in a different specialty, for various reasons.
For example, when a patient is admitted with acute chronic pain, the APS can initiate a new
therapy, resume earlier home therapy or modify existing therapy, increase the dose of a shortterm opioid, or start a long-term opioid.
The service has a total of twelve providers, all of whom are nurse practitioners. Six nurse
practitioners work full-time, and six work part-time.
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Participants
The PI used a purposive sampling strategy to recruit the providers (nurse practitioners) by
sending an e-mail asking them to consider taking part in the research project (see Appendix B).
The e-mail described the intent, scope, and needs of the project. Eleven providers participated in
the project. The study’s inclusion criteria consisted of certified NPs, employed in the acute pain
service, over 18 years old. Exclusion criteria included nurses who were not in an advanced
practice role or employed by the acute pain service. The PI emailed a PowerPoint® presentation
on how to use the DIRE Score and provided ongoing support via telephone, e-mail, and text
throughout the ten-week implementation period.
Ethical Considerations
An Institutional Review Board (IRB) approval was obtained from Georgia College (see
Appendix C), and site approval from Northside Anesthesiology Consultants (see Appendix D),
before the commencement of the project. There was no foreseeable physical or mental risk of
harm to participating providers. The PI practiced complete disclosure about the project,
participation was voluntary, and electronic informed consent forms were signed (see Appendix
E). Providers were given the choice to opt-out at any time during the process, and informed that
they would experience neither coercion, financial or material incentive, nor consequences from
the organization, whether they participated in the project or not.
Data Security
The data for this project included providers’ responses from the surveys and the DIRE
Scores. Data collected were reported in aggregate; no form of identification linked patient or
participant responses, to assure anonymity and confidentiality. The completed DIRE Scores were
stored in a locked box, and only the PI had access. Electronic data was stored and encrypted on a
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personal password-protected computer that was accessed solely by the PI. Data was analyzed
using Statistical Package for Social Science (SPSS ® Version 25). The PI will retain all records
for a minimum of three years, in compliance with the Georgia College research policy, and will
then shred the paper files and wipe electronic files with professional software.
Measures/Tools/Instruments
Survey Instrument
The PI created the post-implementation questionnaire survey instrument (see Appendix
F). It consisted of six items, including five open-ended questions and one close-ended question.
These questions were used to obtain data about the providers’ feedback after using DIRE Score
for ten weeks. Survey Monkey®, an online survey service, was used to host and distribute the
questionnaire.
Risk Assessment Instrument
The DIRE Score was selected as the opioid risk assessment tool used in this project. This
clinician-rated tool, which takes less than two minutes to administer, is used to screen patients
who are potential candidates for long-term opioids, for opioid risks and compliance with the
medication regimen (Belgrade et al., 2006). The PI obtained permission from Dr. Miles
Belgrade, the DIRE Score creator, to use the DIRE instrument (see Appendix G).
The DIRE Score is a 7-item opioid assessment tool developed in 2006 by Dr. Belgrade,
who tested its validity with a retrospective study. The score is made up of four factors:
Diagnosis, Intractability, Risk, and Efficacy Score. The assessment, based on a 3-point scale, is
performed by the provider. A score of 1 correlates to behaviors indicative of a negative
prediction, and a score of 3 indicates appropriateness for treatment with opioids. The categories
that make up the DIRE Score are described below.
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Diagnosis: the patient is rated according to their condition. A patient with benign chronic
conditions with minimal objective findings is rated 1. A patient with a slowly progressive
condition with moderate pain is rated 2. A patient with a progressive condition that is concordant
with severe pain with objective findings is rated 3.
Intractability: the patient is rated according to the number of pain management therapies
they have tried. A patient who has tried few therapies and occupies a passive role in the pain
management process is rated 1. A patient who has tried most customary therapies is rated 2. A
patient who is fully engaged in a spectrum of therapies with inadequate responses is rated 3.
Risk is made up of four subcategories:
Psychological health: the patient is rated according to their psychological health.
A patient with a severe personality disorder or mental illness interfering with care is rated
1. A patient with a moderate personality disorder or mental illness interfering with care is
rated 2. A patient with no significant mental illness is rated 3.
Chemical health: the patient is rated according to their chemical health. A patient
with active or very recent use of illicit drugs or prescription drug abuse is rated 1. A
patient who uses medications to cope with stress is rated 2. A patient with no history of
chemical dependency is rated 3.
Reliability: the patient is rated according to their compliance with their
healthcare. A patient with numerous medical misuse problems and missed appointments
is rated 1. A patient with occasional difficulties with compliance is rated 2. A patient who
is highly reliable with medications, appointments, and treatment is rated 3.
Social support: the patient is rated according to their level of social support. A patient
with their life in chaos with little family support is rated 1. A patient with a reduction in
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some relationship is rated 2. A patient with a supportive family who is involved in work
or school is rated 3.
Efficacy: patients are rated according to how effective their regimen has been. A patient
who experiences minimal pain relief despite moderate or high doses of opioids is rated 1. A
patient who experiences a moderate benefit is rated 2. A patient with good improvement in pain,
with stable doses over time, is rated 3.
The total score varies from a minimum of 7 to a maximum of 21. Scores greater than 14
are predictive of good patient compliance and treatment (Ferrari et al., 2014).
Acute Pain Service Rounding Sheet
An acute pain service rounding sheet is a form of a daily written report used by an APS to
document a patient’s assessment and opioid regimen plan (see Appendix H). Any modifications
to the patient’s plan are also documented on the sheet. This allows continuity of care as providers
may not see the same patients every day. Patients started on long-term opioids were documented
on the APS rounding sheet.
Data Analysis
The dependent variable in this project is the number of long-term opioid therapies initiated
and the number of patients recommended for referral to an addiction specialist. After data
collection, all additional variables were identified, coded, and entered into IBM SPSS® Version
25 for analysis. The following clinical questions were analyzed as follows:
Clinical Question 1: What are providers’ initial plans and final plans for initiating longterm opioid use in acute pain service patients? This question was answered using
descriptive statistics (frequencies and percentages for each initial and final plan).
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Clinical Question 2: What is the relationship between providers’ initial plans for
initiating long-term opioid use in acute pain service patients and their final plans for
initiating long-term opioid use? This question was answered using McNemar’s test.
Clinical Question 3: What is the relationship between patients’ risk level and providers’
final plans for initiating long-term opioid use? This question was answered using
McNemar’s test.
Clinical Question 4: What are providers’ initial plans and final plans for referring acute
pain service patients to an addiction specialist? This question was answered using
descriptive statistics (frequencies and percentages for each initial and final plan).
Clinical Question 5: What is the relationship between providers’ initial plans for
referring acute pain service patients to an addiction specialist and their final plans for
referring acute pain service patients to an addiction specialist? This question was
answered using McNemar’s test.
Clinical Question 6: What is the relationship between patients’ risk level and providers’
final plans for referring acute pain service patients to an addiction specialist? This
question was answered using McNemar’s test.
Clinical Question 7: What percentage of the total number of patients were started on
long-term opioids before and during the project implementation according to the acute
pain rounding sheet? This question was answered using descriptive statistics (frequencies
and percentages before and during implementation).
Clinical Question 8: What is the providers’ utilization of the DIRE Score at two, four,
six, eight, and ten weeks? This question was answered using descriptive statistics
(frequencies and percentages).
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Clinical Question 9: What are providers’ perceptions regarding the DIRE Score after ten
weeks of utilization? This question was answered using descriptive narratives.
Summary
This chapter described the implementation of this quality improvement project. It
described the project design, its setting, the participating providers, and the relevant ethical
considerations. The data collection tools were described, as well as the methods for measuring
and analyzing each of the nine clinical questions. Chapter 4 will communicate the findings of
this study.
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Chapter IV: Results
Stakeholders, such as the CDC, recommend that providers who manage pain must
adequately screen patients before starting long-term opioid therapy. This quality improvement
project aims to improve current opioid risk screening practices in an acute pain service (APS) by
introducing the Diagnosis, Intractability, Risk, and Efficacy (DIRE) Score, an opioid risk
assessment tool, into clinical practice. Purposive sampling was used to recruit the participants
(N=11). Data were collected retrospectively using nine weeks of rounding sheets before project
implementation, and during the 10-week project implementation using the DIRE Score and
rounding sheet. The findings from the project will be discussed in this chapter.
Categories of findings include providers’ demographics, relationships between initial
plans and final plans to start long-term opioids or refer patients to an addiction specialist, the
relationship between patients’ risk levels and providers’ final plans to initiate opioids or refer to
an addiction specialist, and, lastly, providers’ utilization of the DIRE Score and its perception.
Sample Characteristics
The study participants consisted of 11 providers from the APS who provided pain
management for a metro Atlanta hospital. All providers completed the informed consent and
agreed to participate in the project. All 11 providers were female (100%) and held a master’s
level of education (100%). Six (54.54%) of the providers worked full-time, while five (45.45%)
worked on a per diem basis. Specific demographic data, such as age, race, and years of
experience, were not collected in order to protect confidentiality. Table 1 summarizes the
demographic characteristics of the sample population.
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Table 1
Sample Characteristics
Characteristics

n

%

Male

0

0

Female

11

100

11

100

Full time

6

54.54

Per Diem

5

45.45

Gender

Level of Education
MSN/NP
Work Status

N=11 providers
The Statistical Package for Social Sciences (SPSS)® version 25 software was used for
data entry and analysis. All data entries were verified twice. Data analysis began with an
evaluation for missing data and standard data cleaning. No missing data or outliers were
identified. Data were assessed for the need for manipulation, and it was determined no
manipulation was necessary. The normality test was assessed for all interval/ratio (I/R) variables
of the DIRE Scores using Fisher’s exact test for skewness and kurtosis. Total scores (I/R)
variables were normally distributed with skewness of -0.24 (SE= 0.33) and kurtosis of -0.63(SE=
0.65).
DIRE Score Instrument
The DIRE Score was used to screen patients who were being considered for long-term
opioid management. The Cronbach alpha for the DIRE Score in this study was .80, indicating
adequate internal consistency and exactly matching that of the original study. Table 2 displays
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descriptive statistics for the DIRE Score instrument and internal consistency reliability
coefficients for the DIRE Score factors and subcategories.
The providers evaluated 51 patients (N=51) using the DIRE Score opioid risk assessment
tool. The mean total score from the DIRE Score was 15.63 (3.2). The most frequently observed
diagnosis category was “slowly progressive condition” (n = 23, 45%); the most frequent
intractability categories were “most customary treatments have been tried” and “patient fully
engaged in a spectrum of appropriate treatments” (n=23, 41%). The most frequently observed
psychological category was “personality or mental health interferes moderately” (n = 31, 61%),
that of chemical category was “no CD history” (n = 29, 57%), and the most frequent reliability
categories were “highly reliable patient with meds” and “appointments & treatment” (n = 22,
43%). The most frequently observed social support category was “reduction in some
relationships and life roles” (n = 25, 49%), and that of efficacy was “moderate benefit with
function improved in a number of ways” (n = 24, 47%). Table 2 displays descriptive statistics for
the DIRE Score instrument.
Table 2
Descriptive Statistics for the DIRE Score Instrument
DIRE Score

n

%

Diagnosis
1 = "Benign chronic condition"

11

21.6

2 = "Slowly progressive condition"

23

45.1

3 = "Advanced condition"

17

33.3

Intractability
1 = "Few therapies have been tried"

9

17.6

Cronbach

Mean

SD

Range

2.12

0.74

1-3

.80

2.24

0.73

1-3

.81

alpha
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DIRE Score
2 = "Most customary treatments have
been tried"

n

%

21

41.2

21

41.2

42
Cronbach

Mean

SD

Range

9.37

2.18

4-12

.77

2.31

0.72

1-3

.78

2.39

0.77

1-3

.72

2.27

0.72

1-3

.75

alpha

3 = "Patient fully engaged in a
spectrum of appropriate treatments"
Risk(P+C+R+S)
Psychological
1 = "Serious personality dysfunction
or mental illness interfering with

2

3.9

31

60.8

18

35.3

care"
2 = "Personality or mental health
interferes moderately"
3 = "Good communication with
clinic"
Chemical
1 = "Active or very recent use of
illicit drugs, excessive alcohol, or

9

17.6

2 = "Chemical coper"

13

25.5

3 = "No CD history"

29

56.9

prescription drug abuse"

Reliability
1 = "History of numerous problems:
medication misuse, missed
appointments, rarely follows through"

8

15.7
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DIRE Score
2 = "Occasional difficulties with
compliance, but generally reliable"
3 = "Highly reliable patient with
meds, appointments & treatment"

n

%

21

41.2

21

43.1

Social Support

43
Cronbach

Mean

SD

Range

2.39

0.60

1-3

.77

1.90

0.72

1-3

.79

alpha

1 = "Life in chaos. Little family
support and few close relationships.

3

5.9

25

49.0

23

45.1

Loss of most normal life roles"
2 = "Reduction in some relationships
and life roles"
3 = "Supportive family/close
relationships. Involved in work or
school and no social isolation"
Efficacy Score
1 = "Poor function or minimal pain
relief despite moderate to high doses"
2 = "Moderate benefit with function
improved in a number of ways"

16

31.4

24

47.1

11

21.6

3 = "Good improvement in pain and
function and quality of life with
stable doses over time"
a

N= 51 number of DIRE Score forms completed by the providers
Summary
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Results by Clinical Question
Clinical Questions
Of the 51 patients in the sample, 13 scored between 7-13 (not a suitable candidate for
long-term opioids), while 38 scored 14-21 (may be a good candidate for long-term opioid
management).
Clinical Question 1: What are providers’ initial plans and final plans for initiating longterm opioid use in acute pain service patients?
Descriptive statistics were used to analyze the initial plans to start long-term opioids (preDIRE Score) and the plans to initiate long-term opioid use after the DIRE Score (post-DIRE
Score). The providers completed 51 DIRE Score forms (N=51).
Findings revealed that the providers decided not to initiate long-term opioids on 33
(64.7%) patients pre-DIRE Score and 34 (66.7%) patients post-DIRE Score. Comparably, the
providers decided to initiate long-term opioids on 18 (35.3%) patients pre-DIRE Score and 17
(33.3%) patients post-DIRE Score. Table 3 presents the findings of the descriptive statistics.
Table 3
Descriptive Statistics for Providers’ Plans for Initiating Long-Term Opioids
n

%

33
18

64.7
35.3

Initial plans (LTO PRE-DIRE Score)
No
Yes

Final Plans (LTO POST-DIRE Score)
No
34
Yes
17
N= 51: Number of DIRE Score forms completed by the providers

66.7
33.3
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Clinical Question 2: What is the relationship between providers’ initial plans for initiating
long-term opioid use in acute pain service patients and providers’ final plans for initiating
long-term opioid use?
A McNemar’s test was completed to determine the change in providers’ decisions to
initiate long-term opioid treatment between the initial plan (pre-DIRE Score) and post-DIRE
Score. According to the results, the percentage of decisions to initiate long-term opioid treatment
before and after using the DIRE Score was not significantly different (p> 0.05). The providers
decided to initiate 16 (31%) patients on long-term opioid treatment pre-DIRE Score and 17
(33%) post-DIRE Score (N=51). Similarly, they decided against long-term opioids on 32 patients
(67.7%) before the DIRE Score and the same number after. Two (3.9%) patients placed on longterm opioid treatment pre-DIRE Score were taken off post-DIRE Score. Table 4 presents the
results of McNemar’s test.
Table 4
Frequencies and McNemar’s Test Results for Providers’ Plans for Initiating Long-Term Opioids
Final Plans for long-term
opioids use - POST-DIRE

Total

p-value

Score
No

Yes

No

32

1

33

Yes

2

16

18

34

17

51

Initial plans for long-term
opioid use-PRE-DIRE
Score

Total

N= 51: Number of DIRE Score forms completed by the providers

> 0.05
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Clinical Question 3: What is the relationship between patients’ risk levels and providers’
final plans for initiating long-term opioid use?
McNemar’s test was used to determine whether there was a relationship between
patients’ risk levels and providers’ final plans to initiate long-term opioid use. Findings revealed
a statistically significant relationship (p< 0.05). Patients with high DIRE Score risk levels were
less likely to be initiated on long-term opioids. Twelve (23.5%) patients with high DIRE Score
risk levels were not initiated on long-term opioids; one (2%) patient with a high DIRE Score risk
level was initiated on long-term opioids. Comparably, patients with low DIRE Score risk levels
were more likely to be initiated on long-term opioids. Twenty-two (43.1%) patients with low
DIRE Score risk levels were not initiated on long-term opioids; 16 (31.4%) patients with low
DIRE Score risk levels were started on long-term opioids. Table 5 presents the results of
McNemar’s test.
Table 5
Frequencies and McNemar’s Test Results for Patients’ Risk Levels and Providers’ Plans for
Initiating Long-Term Opioids
Final plans for long-term opioid
use - POST-DIRE Score

Risk Level

Total

Total

p-value

p< 0.05

No

Yes

High

12

1

13

Low

22

16

38

34

17

51

N= 51: Number of DIRE Score forms completed by the providers
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Clinical Question 4: What are providers’ initial plans and final plans for referring acute
pain service patients to an addiction specialist?
Descriptive statistics were used to determine the clinician’s initial plans for referring APS
patients to an addiction specialist (pre-DIRE Score) and their final plans for referring APS
patients to an addiction specialist (post-DIRE Score). A sample of 51 DIRE Score forms were
completed (N=51).
The results show that the providers decided not to refer 38 (74.5%) patients to an
addiction specialist pre-DIRE Score and 39 (76.5%) patients post-DIRE Score. Comparably, the
providers decided to refer 13 (25.5%) patients to an addiction specialist pre-DIRE Score and 12
(23.5%) patients post-DIRE Score. Table 6 presents the findings of the descriptive statistics.
Table 6
Descriptive Statistics for Providers’ Plans for Referring APS Patients to an Addiction Specialist
n

%

38
13

74.5
25.5

39
12

76.5
23.5

Initial plans (RAS PRE-DIRE Score)
No
Yes
Final Plans (RAS POST-DIRE Score)
No
Yes

N= 51: Number of DIRE Score forms completed by the providers
Clinical Question 5: What is the relationship between providers’ initial plans for referring
acute pain service patients to an addiction specialist and their final plans for referring
acute pain service patients to an addiction specialist?
McNemar’s test was performed to determine the changes in providers’ decisions to refer
patients to an addiction specialist between the initial plan (pre-DIRE Score) and after the use of
the DIRE Score. Findings revealed no statistically significant relationship (p> 0.05). The
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providers chose to refer 12 (23.5%) patients to an addiction specialist both pre- and post-DIRE
Score (N=51). They chose not to refer 38 (74.5%) patients pre-DIRE Score and 38 (74.5%) postDIRE Score. One (2%) patient chosen for referral pre-DIRE Score was changed to no referral
post-DIRE Score. Table 7 presents the results of McNemar’s test on Clinical Question
Table 7
Frequencies and McNemar’s Test Results for Providers’ Plans for Referral to an Addiction
Specialist.
Final plans for referral to an
addiction specialist-POST-DIRE

Total

p-value

p> 0.05

Score
No

Yes

No

38

0

38

Yes

1

12

13

39

12

51

Initial plans for referral
to an addiction specialistPRE-DIRE Score

Total

N= 51: Number of DIRE Score forms completed by the providers
Clinical Question 6: What is the relationship between patients’ risk levels and providers’
final plans for referring acute pain service patients to an addiction specialist?
McNemar’s test was used to determine a relationship between patients’ risk levels and
providers’ final plans for referring acute pain service patients to an addiction specialist, and it
was found to be statistically significant (p< 0.05). Patients with high DIRE Score risk levels are
more likely to get a referral to an addiction specialist. Ten (19.6%) patients with high DIRE
Score risk levels were referred to an addiction specialist; three (5.9%) patients in this category
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were not referred. Similarly, patients with low DIRE Score risk levels were less likely to get a
referral to an addiction specialist. Thirty-six patients (70.6%) with low DIRE Score risk levels
were not referred to an addiction specialist; only two (3.9%) patients in this category were
referred. Table 8 presents the results of McNemar’s test.
Table 8
Frequencies and McNemar’s Test Results for Patients’ Risk levels and Providers’ Plans for
Referral to an Addiction Specialist.
Final Plans for Referral to an
addiction specialist -POST-DIRE

Total

p-value

p< 0.05

Score

Risk Level

Total

No

Yes

High

3

10

13

Low

36

2

38

39

12

51

N= 51: Number of DIRE Score forms completed by the providers
Clinical Question 7: What is the percentage of the total number of patients started on long
term opioids before and during the project implementation, according to the acute pain
rounding sheet?
Descriptive statistics were used to analyze the percentage of the total number of patients
started on long-term opioids before and during the project implementation. A total sample of 221
patients were evaluated for pain management by the APS providers. Findings revealed that 114
(51.6%) patients were evaluated for pain management nine weeks before the project
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implementation, and 46 of those (62.2%) were started on long-term opioids. During the ten
weeks of the project implementation, 107 (48.4%) were evaluated for pain management, and 28
(37.8%) were started on a long-term opioid. Table 9 and Table 10 present the findings of the
descriptive statistics.
Table 9
Descriptive Statistics for Number of Long-Term Opioids
Long-Term Opioids

N

%

Sum(n)

%

Before Project Implementation

114

51.6

46

62.2

During Project Implementation

107

48.4

28

37.8

221

100

74

100

Total

N= 221 Total number of patients evaluated, n= 74 actual long-term opioids started on patients
Table 10
Descriptive Statistics for Number of Long-Term Opioids, by week
N

%

Cumulative %

Sum (n)

% Total sum

Week 1

8

3.7

3.6

5

6.8

Week 2

15

6.9

10.4

7

9.5

Week 3

17

7.8

18.1

8

10.8

Week 4

5

2.3

20.4

2

2.7

Week 5

13

6.0

26.2

6

8.1

Week 6

12

5.5

32.7

5

6.8

Week 7

15

6.9

38.5

3

4.1

Week 8

24

11.0

49.3

8

10.8

Week 9

5

2.3

51.6

2

2.7

Weeks
Before Project Implementation
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N

%

Cumulative %

Sum (n)

% Total sum

Week 10

7

3.2

54.8

2

2.7

Week 11

5

2.3

57.0

1

1.4

Week 12

13

8.1

62.9

6

8.1

Week 13

3

1.4

64.3

0

0.0

Week 14

14

6.4

70.6

4

5.4

Week 15

12

5.5

76.0

0

0.0

Week 16

24

11.0

10.9

8

10.8

Week 17

8

3.7

90.5

1

1.4

Week 18

13

6.0

96.4

3

4.1

Week 19

8

3.7

100.0

3

4.1

During Project Implementation

N= Total number of patients evaluated for pain management. n= number of long-term opioids
initiated
Clinical Question 8: What is the providers’ utilization of the DIRE Score at two, four, six,
eight, and ten weeks?
Descriptive statistics were used to determine the providers’ utilization of the DIRE Score
at two, four, six, eight, and ten weeks of the project implementation. Findings revealed that at
week two, six DIRE Score forms were utilized. At week eight, 15 DIRE forms were utilized, and
at the final checkpoint, ten weeks, 21 DIRE Score forms were utilized. One hundred and seven
patients were evaluated in ten weeks, and the providers completed 51 DIRE Score forms, which
is almost half of the total number of patients assessed for pain management. Tables 10 and 11
present the findings for Clinical Question 8.
Table 10
Descriptive Statistics of Providers’ Utilization Rate of the DIRE Score: Forms Completed
Weeks Interval

N

% of Total N

% of Total Sum

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL

52

Week 1 through 2

6

11.8

1.7

Week 3 through 4

2

3.9

2.2

Week 5 through 6

7

13.7

10.1

Week 7 through 8

15

29.4

31.3

Week 9 through10

21

41.2

54.7

Total

51

N=51 completed DIRE Score forms.
Table 11
Descriptive Statistics of Providers’ Utilization Rate of the DIRE Score: Patients Evaluated
During Project Implementation

N

%

n

%

Week 1

7

3.2

6

11.8

Week 2

5

2.3

0

0

Week 3

13

5.9

0

0

Week 4

3

1.4

2

3.9

Week 5

14

6.4

6

11.8

Week 6

12

5.5

1

2.0

Week 7

24

11.0

8

15.7

Week 8

8

3.7

7

13.7

Week 9

13

6.0

14

27.5

Week 10

8

3.7

7

13.7

Total

107

51

N= Total number of patients evaluated. n= number of DIRE Score forms completed
Clinical Question 9: What are providers’ perceptions regarding the DIRE Score after ten
weeks of utilization?
Descriptive narratives were used to qualitatively analyze providers’ perceptions
regarding the DIRE Score after ten weeks of utilization. The PI asked providers for their
opinions of DIRE Score as an opioid risk assessment tool. Responses revealed that half of the
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providers indicated that it was “helpful,” while one-fourth indicated it was “easy,” and it “served
as a guide.” One provider said:
I think the DIRE prompts the provider to consider the deeper aspects of how pain is
impacting each patient and provides some guidance on what needs to be included in the
care plan.
Although most reviews were positive, one participant thought it did not apply to all patients.
When providers were asked to describe the ease of use of the DIRE, three-fourths
thought it was “easy to use.” Another description of this dimension was “simple and selfexplanatory.” Encouragingly, providers found the tool easy to use and adapt into their daily
workflow, attributes of feasible implementation. The providers were asked if they had any
concerns about its use. Although five providers had no concerns, one provider thought it made
them critical of the patient. Another thought it was not inclusive of all patients. Lastly, one
provider indicated that limited upfront knowledge of the patients’ social or drug history made
that aspect difficult to score.
Seven providers chose to continue to use the DIRE Score; only one chose the option to
discontinue. The PI asked those interested in continuing to explain their decision. The majority
said it was helpful with long-term opioid decisions. Other reasons included that it “takes the
some of the guesswork away,” is a “great screening tool for long-term opioid prescription,” and
“helps in deciding if long-acting medications are needed in complicated cases.” One provider
said, “I think using the DIRE is encouraging for providers, [since it helps] to know that there are
tools out there to guide in safe decision making in regards to managing pain.”
Summary
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At the end of the project implementation, nine clinical questions were analyzed. In terms
of the providers' initial and final plans to initiate long-term opioid therapy, findings revealed no
statistically significant relationship. However, the results indicated a statistically significant
relationship between the patient's risk level and providers' decision to initiate long-term opioid
therapy.
Similarly, the providers' initial and final plans to refer patients to an addiction specialist
revealed no statistically significant relationship. However, the relationship between a patient's
risk level and providers' decision to refer patients to an addiction specialist proved statistically
significant.
The percentage of long-term opioids initiated during the ten weeks of project
implementation decreased compared to nine weeks before the project implementation. The
providers’ DIRE Score utilization increased weekly, and most providers thought the DIRE Score
was easy to use, helpful, and a guide during long-term opioid decision making.
The last chapter will discuss the study results, as well as its strengths, limitations, and
implications for practice, and future recommendations.

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL

55

Chapter V: Discussion
The Study
This DNP project aimed to provide APS providers with an objective method to screen
patients for opioid risks. The project introduced the Diagnosis, Intractability, Risk, and Efficacy
(DIRE) Score, an opioid risk assessment tool, into the clinical practice. The literature revealed
that the use of opioid risk assessment tools can help detect aberrant behaviors, support clinical
decision making, and boost providers’ confidence levels when deciding to initiate opioid therapy
(Webster & Webster, 2005; Larance et al., 2015; Moore et al., 2009; Jones et al., 2015; Varney et
al., 2018). This chapter will discuss the sample’s demographics, study results, limitations,
implications for practice, and recommendations for future study.
Participants in this project were all female providers working in an acute pain service. A
U.S. Department of Health and Human Services survey of nurse practitioners in 2012 showed
that the NP workforce is largely homogenous in gender, with male practitioners making up only
7% of the survey pool. About 86% of participants were white, 5% were black, and about 84%
held a graduate degree (U.S. Department of Health and Human Services, 2014).
The PI educated providers on how to use the DIRE Score. Their decisions to initiate longterm opioid therapy for patients before and after using the DIRE Score were recorded, as were
their decisions to refer patients to an addiction specialist before and after using the DIRE Score.
Long Term Opioid Initiation
The providers’ initial plans to initiate long-term opioids did not differ from their final
plans after using the DIRE Score. The project’s findings also indicate no significant relationship
in the percentage of providers who decided to start long-term opioid treatment before and after
using the tool. These results suggest that, although researchers postulated that the DIRE Score
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would substantially assist the providers’ clinical decisions, it is more accurate to say that it
validated their initial assessments and interventions. The relationship found between patients’
risk levels and providers’ final plans to initiate long-term opioids echoed the original study used
to validate the DIRE Score, which showed that its score demonstrated a strong correlation with
compliance with opioid treatment (Belgrade, 2006). Therefore, it was reasonable for providers
not to initiate long-term opioid therapy on high-risk patients.
In comparison, patients with low DIRE Score risk levels, those less likely to abuse
opioids or refuse to comply with therapy, were more likely to be initiated on long-term opioids.
However, providers did not initiate long-term opioids on some patients with low-risk levels,
probably because they did not require long-term opioid therapy. Jovey (2012) stated that without
risk factors, it is unlikely that an individual will develop an addiction disorder, but will rather
take the medication appropriately, as prescribed for pain.
Referral to Addiction Specialist
The providers’ plans to refer patients to an addiction specialist did not differ from pre- to
post-DIRE Score. The project’s findings also indicated no significant changes in providers’
decisions to refer patients to an addiction specialist before and after using the DIRE Score. Based
on the PI’s personal clinical experience, patients referred to an addiction specialist usually
displayed aberrant behaviors. Examples of aberrant behaviors include using additional opioids
alongside those prescribed, forging a prescription, soliciting opioids from other providers,
reporting lost or stolen prescriptions, requesting early refills, and having a history of overdose
(Webster & Webster, 2005).
Similarly, Larance et al.’s (2015) study using the Opioid-Related Behaviors in Treatment
(ORBIT) scale to detect aberrant behavior also concluded that the ORBIT prompts clinical
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decisions and helps providers pinpoint aberrant behavior. The PI’s experience as an acute pain
provider suggests that when providers recognize these behaviors in their patients, they are likely
to refer them to an addiction specialist even without using an opioid risk assessment tool.
The study found a statistically significant relationship between patients’ risk levels and
providers’ final plans for referring APS patients to an addiction specialist. The project’s findings
indicated that patients with high DIRE Score risk levels were more likely to get a referral to an
addiction specialist. High-risk patients were more likely to abuse opioids and needed a higher
level of expertise to assess their addiction treatment needs.
In comparison, patients with low DIRE Score risk levels were least likely to get a
referral to an addiction specialist. They did not need a referral because they were less likely to
misuse opioids and more likely to comply with the opioid regimen. This is similar to Jamison et
al.’s (2016) study that assessed the efficacy of the Opioid Compliance Checklist (OCC) and
concluded that patients who scored lower on the OCC showed greater compliance with their
opioid medication.
DIRE Score Utilization and Providers’ Perception
This study used the Effectiveness, Adoption, and Implementation subsets of RE-AIM
framework to evaluate whether the DIRE Score could be used to accurately gauge providers’
perception. The number of long-term opioids initiated nine weeks before the project’s
implementation dropped by 24.4% by ten weeks into the project’s implementation. This decrease
could result from several different factors, such as the number of high-risk or low-risk patients
evaluated during those periods, or providers’ raised awareness about the risks of long-term
opioid therapy exposed by the DIRE Score, leaving them more hesitant to prescribe. Since the
rise in opioid use disorder has been attributed to increased opioid prescriptions, decreasing the
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number of patients started on long-term opioid therapy could help ease the epidemic by reducing
the pool of potential abusers.
The DIRE Score’s effectiveness was evaluated in the RE-AIM framework. Its utilization
increased as the weeks passed, indicating promise that providers may be willing to adopt the
DIRE Score more permanently in their practices. Providers in the study seemed more compliant
in using the DIRE Score when they received frequent reminders. A meta-analysis by Mayer and
Fontelo (2017) on the effect of text message reminders for HIV-related compliance supports this
relationship.
Providers’ perception of the DIRE Score after completing the project was promising, and
the influx of positive feedback demonstrated its effectiveness. They recognized that the DIRE
Score made them think about important factors that should influence whether a patient is
prescribed opioids, such as how pain impacts each patient, their diagnosis, social support,
chemical health, reliability, and psychological makeup. They also acknowledged that the DIRE
Score was straightforward, easy to use, and helpful in making long-term opioid decisions,
especially for complex cases. Similarly, Pearson et al.’s (2017) study concluded that providers’
confidence was associated with both a protocolized, consistent, practice-based approach towards
managing opioids and the perceived ability to identify patients at risk for opioid misuse. Seven of
the eight providers (87.50%) who completed the survey acknowledged that they would continue
to use the DIRE Score in clinical practice to screen for and assess the risk of noncompliance,
opioid abuse, and opioid misuse in patients requiring pain management.
Providers perceived a similar provider-administered opioid screening tool, the Pain
Assessment Documentation Tool (PADT), as equally or identically helpful when compared to
the DIRE. Passik (2004) found that the PADT was considered useful in guiding clinicians’
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evaluation of possible outcomes of opioid therapy, such as pain relief, patient functioning,
adverse events, and drug-related behaviors.
Strengths and Limitations
One of this study’s strengths was complete support from the APS director, manager, and
providers. All providers participated in the project, which made the implementation and followup easy. The projects’ small sample size was helpful when it came to educating the providers and
gaining their support. This work also introduced a standardized screening tool for risk of opioid
regimen non-compliance into an environment with no such guidelines in practice. In keeping
with the aims of this project, the DIRE Score will equip providers with the kind of standardized
screening approach that is necessary for quality improvement of care.
The primary limitation was the small sample size of 11 providers, which may have
affected the study's impact by increasing the possibilities for errors. The on-going COVID-19
pandemic affected the number of DIRE Score forms completed (N=51) in ten weeks. Five out of
the 11 providers worked on a per diem basis; as the pandemic caused a reduction in providers’
work hours, fewer were available to regularly utilize the DIRE Score.
Also, this study used a homogenous sample of nurse practitioners, making it difficult to
replicate with different providers. The limited pool of providers led the PI to employ
convenience sampling rather than random sampling to obtain project participants, making the
results difficult to generalize to other practices, or to other professionals, such as physicians and
pharmacists. Additionally, the providers’ repeated use of the DIRE Score opened up the potential
for bias as they grew more comfortable over time.
Recommendations for Future Research
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Recommendations for further study include using more healthcare providers, such as
physicians and physician assistants who deal with pain management, and extending the study’s
run time and sample size to increase validity. For ease of convenience and reduction in human
error, it is recommended that researchers use more advanced technology, such as the free
Apple® app version of the DIRE Score to calculate the DIRE Score, collect and analyze data.
Further research is needed to determine if the DIRE Score validates other providers’ clinical
decisions, such as physicians and physician assistants, in inpatient or outpatient settings.
In addition, future research should take the novel approach of using the DIRE Score
concurrently with the prescription drug monitoring program (PDMP) to study its validity. By
using PDMP, providers can confirm prescription opioids and notice irregularities, like multiple
prescriptions by different doctors in the same month, which may prompt them to complete DIRE
Score screenings to better guide their patients’ treatment plans.
Finally, due to a gap in existing literature, further research using the DIRE Score and
other screening tools to detect opioid abuse and/or misuse in acute care settings is recommended.
As Harle et al. (2015) proposed, clinical leaders, educators, and policymakers should continue
creating and disseminating good evidence-based education on chronic pain and opioid risk
assessment.
Implications for Future Practice
The DIRE Score validated providers’ initial assessments and interventions, making it a
promising tool for objective assessment. If implemented widely, the DIRE Score would promote
safe prescribing practices using recommended guidelines, which would increase patient safety.
Providers who use the DIRE Score are more likely to identify patients at risk for opioid misuse
and refer them to an addiction specialist. Since this early detection of risk may prevent misuse,
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overdoses, and deaths, tools like the DIRE Score are essential to mitigating the national opioid
crisis.
This project encourages screening patients in acute care settings to determine risk levels
and assess their compliance with long-term opioids. Policies for standardized screening in acute
care settings could have a global impact. For example, integrating the DIRE Score into the
electronic health record will make it easily accessible and allow for automatic scoring for the
provider, likely increasing its utilization. Documenting the DIRE Scores in patients’ charts to
serve as an official record of their risk level is considered a best practice principle. Expanding
use of these tools can correct the assumption that opioid abuse occurs mainly in outpatient
settings.
Sustainability
The project is sustainable. Performing risk assessment is an essential aspect of pain
management because it helps identify patients at risk for opioid misuse, thereby improving
patient safety. Providers should perform this risk assessment before starting patients on opioids
therapy. With this implementation, providers at the APS may now use the DIRE Score risk
assessment tool during pain consultations to assess patients for opioid abuse and/or misuse.
For the DIRE Score to be user-friendly, it needs to be integrated into the EMR so
providers can easily access it anytime they need to assess a patient. To achieve this, the
stakeholders and the PI can work with the hospital’s information technology department to
incorporate it into the current EMR. Providers that have access to an iPhone® can download the
DIRE Score for free and use it anytime. The PI will perform reviews periodically, at least in the
first year, until it is fully integrated into the practice.
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The PI disseminated the project results to the APS providers through a PowerPoint
presentation. This project will also be shared with the Georgia College community through a
virtual poster presentation in the Georgia College Fourth Annual Graduate Research Poster
Exhibit & Competition. The purpose of this dissemination is to educate both providers and the
general public on the benefits of using the DIRE Score as an opioid risk assessment tool in
clinical practice. This could help promote sustainability, change providers' prescribing practices,
promote patient safety, and overall have a positive impact on the opioid epidemic.
Summary
This project was designed to improve the current opioid risk screening practices in an
acute pain service (APS) by introducing the Diagnosis, Intractability, Risk, and Efficacy (DIRE)
Score into clinical practice. This opioid risk assessment tool was introduced based on the
assumption that the DIRE Score would substantially change providers’ prescribing decisions.
After completing the project, the findings revealed that the DIRE Score validated providers’
initial plans to initiate long-term opioids or refer patients to an addiction specialist.
A RE-AIM framework was used to evaluate the process through which this project was
implemented. The adoption and implementation of the DIRE Score contributed to an increase in
the providers’ utilization of the DIRE Score. A decrease in the initiation of long-term opioids
was noted during the project’s implementation, which was one of its direct aims. Implementing
the DIRE Score in the APS will bring about a positive change in prescribing practices by
allowing providers to screen patients in need of long-term opioids to swiftly detect at-risk
patients. Overall, using the DIRE Score will improve patient safety by preventing opioid misuse
and even death, thereby mitigating the opioid crisis.
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Conclusion
This project consisted of the implementation of the DIRE Score in an acute pain service
team in response to the needs assessment of the service. The primary desired outcome was for
providers to use a standardized screening approach, guided by a validated tool, to assess risks
before starting patients on long-term opioid therapy. The study showed that the DIRE Score
validated providers’ decisions to initiate long-term opioids or refer patients to an addiction
specialist. Future iterations of this area of study might strive to promote patient safety by
changing current prescribing practices. Patients for whom long-term opioid therapy would be
inappropriate will be identified based on their DIRE Scores, and providers will make the
appropriate recommendations or referrals before the patient leaves the hospital. This intervention
can prevent opioid-related harms, overdoses, and deaths, and ease the global opioid epidemic.
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Appendices
Appendix A: DIRE Score
Please answer these questions before using the DIRE. Based on your assessment would you
Yes

No

Initiate Long-term Opioids
Recommend referral to an addiction specialist

Please answer these questions after using the DIRE
Yes
Initiate Long-term Opioids
Recommend referral to addiction specialist

No
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Appendix E: Informed Consent
INFORMED CONSENT
Research Topic: Implementation of an Opioid Risk Assessment Tool in an Acute Pain Service.
Principal Investigator:
Emoshoke Owie, APRN, FNP-BC
Georgia College and State University, DNP Student
404-388-4759
emoshoke.owie@gmail.com
I, _________________________________________________, agree to participate in the
research Implementation of an Opioid Risk Assessment Tool in an Acute Pain Service, which is
being conducted by Emoshoke Owie, who can be reached at 404-388-4759. I understand that
my participation is voluntary; I can withdraw my consent at any time. If I withdraw my consent,
my data will not be used as part of the study and will be destroyed.
The following points have been explained to me:
1.

2.

3.
4.
5.
6.

7.

The purpose of this study is to introduce an opioid risk assessment tool, the Diagnosis,
Intractability, Risk, and Efficacy Score (DIRE) into clinical practice that will be used to
screen patients to identify patients at risk for opioid misuse when considered for long
term opioid therapy.
The procedures are as follows: I will need to view a PowerPoint on how to use the DIRE.
I will use the DIRE to screen patients being referred for pain management. It will take
two minutes to use the DIRE. I will take a post-implementation survey after eight weeks
of using the DIRE. The survey may take fifteen minutes to complete.
I will not list my name on the post-implementation survey and the DIRE forms.
Therefore, the information gathered will be confidential.
I will be asked to sign an online consent form. I will print or save for my records.
I may find that some questions are invasive or personal. If I become uncomfortable
answering any questions, I may cease participation at that time.
This research project is being conducted because of its potential benefits, either to
individuals or to humans in general. The expected benefits of this study include
the availability of a standardized opioid-risk assessment tool that can be used to assess
the risks of opioid misuse before prescribing long-term opioids. The tool will also support
clinical decision-making when considering patients for long term opioid therapy. To
humankind, it will help mitigate the ongoing opioid epidemic by possibly reducing the
number of deaths caused by opioid abuse and or misuse when “at-risk” patients are
identified and referred to the appropriate specialty.
I am not likely to experience physical, psychological, social, or legal risks beyond those
ordinarily encountered in daily life or during the performance of routine examinations or
tests by participating in this study.
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9.
10.
11.
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My responses will be confidential and will not be released in any individually identifiable
form without your prior consent unless required by law.
The investigator will answer any further questions about the research should I have them
now or in the future (see above contact information).
In addition to the above, further information, including a full explanation of the purpose
of this research, will be provided at the completion of the research project on request.
By signing this form, I am acknowledging that I am 18 years of age or older.

Signature of Investigator

Date

Signature of Participant

Date

Research at Georgia College involving human participants is carried out under the oversight of the
Institutional Review Board. Address questions or problems regarding these activities to the GC
IRB Chair, email: irb@gcsu.edu.
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Appendix F: Post-Implementation Survey
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78

IMPLEMENTATION OF AN OPIOID RISK ASSESSMENT TOOL
Appendix H: Acute Pain Rounding Sheet

79

